Thymosin Beta-4
Also known as: Thymosin β4, Tβ4, TB4, TMSB4X protein product
4 notable studies · 4 references
TLDR
Thymosin Beta-4 is an endogenous 43-amino-acid actin-binding peptide with extensive preclinical tissue-repair research and direct human clinical studies involving intravenous administration, wound healing, and ophthalmic applications, but those findings belong to full-length Tβ4 and should not automatically be attributed to the shorter research-market compound TB-500.
Research Supports
- Studied for actin regulation and cytoskeletal control via G-actin binding
- Investigated for wound healing, cell migration, and angiogenesis
- Examined in corneal repair, including dry eye and neurotrophic keratopathy
- Studied for cardiac repair and cardiomyocyte survival
- Has direct human administration research, unlike the shorter fragment TB-500
Observations Reported in Research
- Generally well tolerated with no dose-limiting toxicity in a 40-participant IV Phase I safety/PK study (Ruff et al., 2010)
- A topical 0.03% concentration produced a signal suggesting accelerated wound healing in a 73-patient venous-ulcer trial (2010)
- Improved ocular discomfort and corneal staining in a 72-participant dry-eye Phase II trial (Sosne & Ousler, 2015)
- Complete healing at 4 weeks occurred in 6 of 10 treated neurotrophic-keratopathy patients vs 1 of 8 on placebo, not conventionally significant (2022/2023)
These are brief summaries of what the referenced research examined or reported — not conclusions about safety or effectiveness, and not medical advice. See Notable Studies and Sources & References below for the full context and citations.
At a Glance
Classification: Endogenous 43-amino-acid actin-binding peptide; beta-thymosin family peptide; regenerative and cytoskeletal regulatory peptide
Thymosin Beta-4 is a naturally occurring 43-amino-acid peptide found widely throughout human tissues and body fluids. Its best-established molecular role is binding G-actin, helping regulate the pool of actin available for cytoskeletal assembly. But research has connected Tβ4 with a much broader collection of processes: • Cell migration • Wound repair • Angiogenesis • Inflammation • Corneal healing • Tissue protection • Cardiac repair • Hair-follicle biology Most importantly for Aminodex: Thymosin Beta-4 is not TB-500. Tβ4 is the full-length endogenous 43-amino-acid peptide. TB-500 is a shorter synthetic fragment associated with an actin-binding region of Tβ4. A huge amount of research-market content quietly transfers evidence from full-length Tβ4 to TB-500. We shouldn't. Full-length Tβ4 actually has human clinical research, including intravenous Phase I testing and topical/ophthalmic clinical trials.
What Is Thymosin Beta-4?
Thymosin Beta-4 was originally isolated from thymic tissue, which explains its name. But it isn't primarily a thymic hormone. Tβ4 is broadly distributed throughout the body and is particularly abundant in: • Platelets • Wound fluid • Macrophages • Many other cell types. Its sequence contains the highly conserved actin-binding motif: LKKTETQ which is central to its interaction with G-actin. By sequestering monomeric actin, Tβ4 helps regulate: actin polymerization → cytoskeletal remodeling → cellular movement. That's particularly relevant during tissue repair, when cells need to migrate into damaged areas.
What Are Researchers Studying?
Wound healing
This is one of the strongest areas of Tβ4 research. Experimental evidence suggests Tβ4 can influence several processes necessary for wound repair: • Keratinocyte migration • Endothelial-cell migration • Collagen deposition • Angiogenesis • Inflammatory signaling Animal studies showed accelerated healing in normal, diabetic and aged animals. Importantly, this work progressed into humans. Phase 2 research involving venous stasis ulcers reported an acceptable safety profile and a signal suggesting that a particular topical Tβ4 concentration might accelerate wound closure.
Corneal repair
The eye has become one of the most clinically developed applications of Tβ4. An ophthalmic formulation known as RGN-259 has been investigated for: • Dry eye • Neurotrophic keratopathy • Corneal epithelial injury. A randomized Phase II dry-eye study enrolled 72 participants and found improvements in several ocular signs and symptoms, although not every endpoint behaved consistently. Later neurotrophic-keratopathy research also produced encouraging healing signals.
Cell migration
Cell migration is one of the connecting threads across Tβ4 biology. Repairing tissue requires: cells to move → organize → rebuild damaged structures. Through actin regulation and additional signaling effects, Tβ4 can influence movement of: • Keratinocytes • Endothelial cells • Other repair-associated cell populations. This provides a plausible mechanistic bridge between its basic cytoskeletal function and wound-healing effects.
Angiogenesis
Tβ4 has demonstrated pro-angiogenic activity in experimental systems. Formation of new blood vessels can be beneficial during tissue repair because injured tissue requires restored circulation. But this also illustrates why calling Tβ4 simply a “healing peptide” is too vague. Angiogenesis is biologically powerful and context-dependent. A process that helps repair damaged tissue can have different implications in pathological settings.
Inflammation
Tβ4 and metabolites derived from it have been investigated for anti-inflammatory and inflammation-resolving effects. Researchers have reported modulation of: • inflammatory-cell recruitment • cytokine signaling • tissue inflammatory responses. This may contribute to its effects in wounds and ocular injury. But Tβ4 shouldn't simply be labeled an “anti-inflammatory peptide”; its biology is substantially broader.
Cardiac injury
Tβ4 has attracted substantial interest in cardiovascular research because experimental models suggested effects on: • Cardiomyocyte survival • Vascular development • Cell migration • Cardiac repair. This interest was strong enough that intravenous synthetic Tβ4 underwent formal human safety and pharmacokinetic testing. However, human safety/PK research does not establish that Tβ4 regenerates damaged human heart muscle.
Tissue regeneration
Tβ4 is often grouped into “regenerative peptides,” and unlike many compounds carrying that label, there is substantial mechanistic evidence supporting roles in tissue repair. A 2016 review summarized extensive preclinical wound-healing research plus human Phase 2 experience. Still: supporting tissue-repair pathways ≠ regenerating any injured human tissue on demand.
How Does It Work?
There probably isn't one mechanism. Actin regulation Tβ4 ↓ binds monomeric G-actin ↓ regulates actin polymerization ↓ affects cytoskeletal remodeling and cell migration. Tissue repair Experimental research additionally implicates: • endothelial migration • keratinocyte migration • angiogenesis • collagen deposition • inflammatory regulation • resistance to apoptosis. These processes overlap during wound healing. This multi-pathway biology is one reason Tβ4 has been investigated across seemingly unrelated tissues.
What Does the Research Show?
Human research
Unlike TB-500, full-length Tβ4 has direct human administration evidence. A randomized placebo-controlled study administered intravenous synthetic Tβ4 to healthy volunteers across ascending single and repeated doses. Forty subjects participated across four dose cohorts, followed by daily dosing for 14 days. Treatment was reported as generally well tolerated without dose-limiting toxicity or serious adverse events during the study. Another first-in-human study evaluated recombinant human Tβ4 in healthy Chinese volunteers. Clinical research also includes: • Venous ulcers • Pressure ulcers • Dry eye • Neurotrophic keratopathy. So the evidence hierarchy here is substantially stronger than for TB-500.
Animal research
Extensive. Animal models include: • Dermal wounds • Diabetic wounds • Aging • Burns • Corneal injury • Cardiac injury • Neurological injury. A classic 2003 experiment found accelerated dermal repair in both diabetic and aged mice following Tβ4 treatment.
In-vitro research
Extensive mechanistic research supports effects involving: • Actin • Cell migration • Angiogenesis • Apoptosis • Inflammatory signaling • Cellular differentiation. This is a case where the molecular and cellular foundation is considerably stronger than for many research-market peptides.
Notable Studies
A Randomized, Placebo-Controlled, Single and Multiple Dose Study of Intravenous Thymosin Beta4 in Healthy Volunteers
humanForty healthy participants received ascending intravenous doses of synthetic Tβ4 or placebo, followed by repeated daily exposure for 14 days. The study characterized human pharmacokinetics and reported that treatment was generally well tolerated, with no dose-limiting toxicity or serious adverse events during the study.
Limitations: Healthy-volunteer safety/PK study, not an efficacy trial. Short treatment and follow-up cannot establish long-term safety.
View publication →The Effect of Thymosin Treatment of Venous Ulcers
humanSeventy-three patients with venous stasis ulcers were randomized across topical Tβ4 dose groups and placebo. Treatment was generally comparable to placebo for safety, while the 0.03% concentration produced a signal suggesting accelerated wound healing in some patients.
Limitations: Relatively small dose-ranging trial; the efficacy signal was not uniform across doses or patients.
View publication →Thymosin Beta 4 Ophthalmic Solution for Dry Eye: A Randomized, Placebo-Controlled, Phase II Clinical Trial Conducted Using the Controlled Adverse Environment Model
humanSeventy-two participants with moderate-to-severe dry eye were randomized to 0.1% Tβ4 ophthalmic solution or placebo for 28 days. The study reported encouraging improvements in several measures of ocular discomfort and corneal staining.
Limitations: Single-center study with a modest sample and a specialized controlled-adverse-environment model. Findings do not establish systemic Tβ4 efficacy.
View publication →0.1% RGN-259 (Thymosin β4) Ophthalmic Solution Promotes Healing and Improves Comfort in Neurotrophic Keratopathy Patients in a Randomized, Placebo-Controlled, Double-Masked Phase III Clinical Trial
humanAmong a very small group of patients with neurotrophic keratopathy, complete healing at four weeks occurred in 6 of 10 Tβ4-treated patients versus 1 of 8 placebo recipients; the primary comparison did not reach conventional statistical significance at that point, although later healing and symptom measures produced encouraging signals.
Limitations: Extremely small sample. Several endpoints were trends rather than conventionally significant primary results, so the findings require larger confirmatory evidence.
View publication →What We Still Don't Know
• Which systemic indications, if any, provide clinically meaningful benefit • Long-term systemic safety • Optimal route and formulation by indication • Whether cardiac findings translate into meaningful human outcomes • Which regenerative effects are clinically important versus laboratory phenomena • Whether benefits generalize beyond specific wound/ocular contexts • Long-term implications of pro-angiogenic signaling • Whether research-market material matches pharmaceutical-grade Tβ4 • Which biological effects require intact Tβ4 versus metabolites/fragments.
Related Compounds
Recent publications
Latest titles from PubMed, not reviewed by Aminodex. Not an endorsement. See all on PubMed ↗
Take the Thymosin Beta-4 research with you.
Get the Aminodex Thymosin Beta-4 Brief—a concise summary of the research, notable studies, evidence types, limitations, and references.
One-time email. We do not add you to any mailing list.
Sources & References
- Ruff D, Crockford D, Girardi G, Zhang Y. A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers. 2010.
- Treadwell T, Kleinman HK, Crockford D, et al. The regenerative peptide thymosin β4 accelerates the rate of dermal healing in preclinical animal models and in patients. 2012.
- Sosne G, Ousler GW. Thymosin beta 4 ophthalmic solution for dry eye. 2015.
- Sosne G, et al. RGN-259 in neurotrophic keratopathy. 2022/2023.
Supplier Listings
A directory of relevant research suppliers for this compound is not yet available.